Results 241 to 250 of about 15,550,459 (307)

Dynamic risk assessment by landmark modeling of the restricted residual mean survival time. [PDF]

Lifetime Data Anal
Zhang Y, Schaubel DE.
europepmc   +1 more source

SPRED2 Negatively Regulates CD8+ T Cell‐Mediated Antitumor Immunity in Breast Cancer

Advanced Science, EarlyView.
Sprouty‑related EVH1 domain containing 2 (SPRED2) restrains Ras/Raf/ERK signaling in CD8+ T cells. Host SPRED2 deficiency enhances T‐cell survival, cytotoxicity, and memory‐like phenotypes, reducing primary tumor growth and endpoint lung metastatic burden in breast cancer models.
Miao Tian, Teizo Yoshimura, Kun Zhao, Chunning Li, Tong Gao, Ziyi Wang, Masayoshi Fujisawa, Toshiaki Ohara, Akihiro Matsukawa   +8 more
wiley   +1 more source

Tracking CDK1 Dynamics With a Novel Biosensor Mouse and Clinical Cohorts to Predict CDK4/6 Inhibitor Sensitivity in ER+ Breast Cancer

Advanced Science, EarlyView.
Cyclin‐dependent kinase (CDK) 1 activity is a dynamic marker of treatment response in estrogen receptor positive breast cancer. Patient cohorts reveal CDK1 activity increases during progression to invasive disease, where high expression correlates with poor survival. Using a novel Cdk1 biosensor mouse alongside in vitro models, we demonstrate that CDK1
Sarah Alexandrou, Kristine J. Fernandez, Min Li Huang, Ewan K. A. Millar, Claire Vennin, Leila Eshraghi, Tan Dat Timothy Lam, Victoria Lee, Nyah C. Brooks, Janett Stoehr, Cristian Guaman Mendez, Douglas Strathdee, David Stevenson, David Herrmann, Sandra O'Toole, Paul Timpson, Max Nobis, C. Elizabeth Caldon   +17 more
wiley   +1 more source

Unravelling the Drivers of Early-Life Mortality in Yak Calves: A Retrospective Cohort Study Using Survival Analysis. [PDF]

Animals (Basel)
Debbarma A, Hussain M, Pukhrambam M, Loat S, Paul V, Medhi D, Abedin SN, Sarkar M.   +7 more
europepmc   +1 more source

Drug-Specific Associations of Angiotensin Receptor Blockers With Parkinson's Disease Risk in a Multicenter Electronic Health Record Cohort. [PDF]

Fundam Clin Pharmacol
Tran K, Yang J, Pham S, Luong D, Martin BA, Sasaki S, Hahn J, Luu R, Kim GJ.   +8 more
europepmc   +1 more source

Methods for analyzing recurrent and terminal events considering composite and competing endpoints in clinical trials: a practical overview. [PDF]

BMC Med Res Methodol
Duoerkongjiang A, Zapf A, Kirchhof P, Ozga AK.   +3 more
europepmc   +1 more source

Modeling treatment effects on absorbing outcomes in clinical trials: Leveraging longitudinal and ordinal data for efficiency gains. [PDF]

Stat Methods Med Res
Di Gravio C, Tao R, Nam Y, Schmidt EP, Shapiro N, Schildcrout JS.   +5 more
europepmc   +1 more source

Effects of combining durvalumab with chemotherapy in individuals suffering from advanced biliary tract cancer: an investigation into the prognostic nutritional index, systemic immune-inflammation index and patient survival outcomes. [PDF]

Am J Transl Res
Zhang X, Jin S, Han J, Zhao X.
europepmc   +1 more source